agilon health (AGL) opened 2026 with Q1 revenue of US$1.4b and basic EPS of US$1.80, alongside net income from continuing operations of about US$10.9m and earnings from discontinued operations of US$19m. The company has seen quarterly revenue fluctuate around the US$1.4b to US$1.6b range since early 2024, while trailing 12 month EPS sits at a loss of US$22.53 on net income from continuing operations of US$373.5m. This puts the spotlight firmly on how sustainably these latest margins have been earned.

See our full analysis for agilon health.

With the Q1 scorecard on the table, the next step is to stack these numbers against the most common narratives around agilon health to see which views hold up and which ones the latest margin profile starts to challenge.

Q1 swing to US$29.9m profit against a year of losses

• Q1 2026 net income from continuing operations came in at US$29.9 million, compared with trailing 12 month net income from continuing operations of a loss of US$373.5 million, so the quarter sits against a still loss making year.
• What stands out for the bullish view is that this profitable quarter arrives while trailing 12 month revenue growth sits at 4.9% a year versus 11.4% for the wider US market. This means bulls are leaning on the idea that contract quality, data analytics and partner mix can do more of the heavy lifting than raw top line growth.
  • Bulls highlight higher value contracts, AI driven care management and work with top performing partners as support for better margins, yet the trailing 12 month loss of US$373.5 million shows those improvements are not yet visible over a full year.
  • They also point to a long term industry shift to value based care and quality incentives, but with trailing EPS at a loss of US$22.53, the Q1 profit still needs to be repeated before it really backs up that margin story.

On these numbers, bulls are likely to focus on whether this single profitable quarter is the first step toward the margin profile they expect, or just a temporary improvement before losses resume. It can be useful to line this result up against the more detailed bullish thesis in the 🐂 agilon health Bull Case.

Revenue steadies around US$1.4b while 4.9% growth trails market

• Quarterly revenue has moved between about US$1.4b and US$1.6b since early 2024, with trailing 12 month revenue at US$5.8b and growth of 4.9% a year compared with 11.4% for the US market, so top line progress has been modest against that benchmark.
• Critics in the bearish camp argue that slower growth plus ongoing losses limit the appeal of this model. The recent run of quarterly net income figures, which show three straight quarters of losses in 2025 followed by a single profitable Q1 2026, gives them support to question how durable any improvement really is.
  • Bears point to the trailing loss of US$373.5 million and a five year trend of losses increasing by about 8.6% a year as evidence that profitability has been hard to achieve despite revenue scale above US$5.8b.
  • They also highlight that revenue growth of 4.9% a year sits below the 11.4% market reference, so even with Q1 revenue at US$1.4b, the story is less about rapid expansion and more about whether existing contracts can be run more efficiently.

Skeptical investors often start from this slower growth and loss history when they assess the downside case for the stock. If you want to see how those concerns are built into a fuller argument, it is worth reading through the 🐻 agilon health Bear Case.

P/S at 0.2x and Q1 profit vs DCF fair value tension

• agilon health trades at a P/S of about 0.2x compared with 1.2x for the US Healthcare industry and 2.2x for peers, while the current share price of US$60.66 sits above the stated DCF fair value of about US$31.84. This creates a clear contrast between low revenue multiples and the cash flow based estimate.
• Consensus narrative views this mix as a tug of war between valuation signals and fundamentals, because the trailing 12 month loss of US$373.5 million and EPS loss of US$22.53 are set against comparatively low P/S multiples and a DCF fair value that is below the share price. Investors therefore have to weigh whether the Q1 profit meaningfully changes that longer term picture.
  • On one side, the low 0.2x P/S ratio versus industry and peers can be read as the market pricing in the history of losses and softer 4.9% revenue growth, which is slower than the 11.4% market benchmark.
  • On the other, the gap between the US$60.66 share price and the US$31.84 DCF fair value, combined with a still loss making trailing year, underlines that any thesis built around margin recovery and future earnings needs to be tested carefully against the actual financial track record so far.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for agilon health on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

With both concerns and optimism in the mix, it helps to see the full picture and move quickly from headlines to hard numbers using the 1 key reward and 2 important warning signs.

See What Else Is Out There

agilon health is still working through a trailing loss of US$373.5m, slower 4.9% revenue growth and a share price above its stated DCF fair value.

If that mix of ongoing losses and valuation tension makes you cautious, it is worth shifting some attention toward 72 resilient stocks with low risk scores that aim to prioritize stability and lower downside risk.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.